Genvax Technologies, Inc. is a pioneering animal vaccine startup based in Ames, Iowa. The company specializes in developing next-generation mRNA nanoparticle vaccines aimed at preventing and treating animal diseases. Genvax serves the veterinary and animal health markets, targeting livestock producers, veterinary clinics, and animal health organizations. The business model revolves around research and development, followed by commercialization of their proprietary vaccines. Revenue is generated through the sale of these vaccines to clients in the animal health industry. The company leverages the expertise of its founders, Joel Harris and Dr. Hank Harris, who previously built and sold Harrisvaccines to Merck Animal Health in 2015. Genvax is committed to innovation and rapid response to emerging animal health challenges, striving to make a lasting impact on global animal health.

Keywords: mRNA vaccines, nanoparticle technology, animal health, veterinary, livestock, disease prevention, biotechnology, Ames Iowa, innovation, commercialization.